Grant: Randomized Controlled Trials
University of Calgary
$3,319,686.00
The BK: KIDNI Trial (BK: Kinase Inhibition to Decrease Nephropathy Intervention Trial)
FY 2008-09
Summary
This is a randomized controlled trial to determine whether specific
therapy aimed at reducing viral damage to the transplant kidney
will have a better outcome than standard therapy, which currently
consists of reducing immunosuppression. Infection with the BK
virus in kidney transplants can lead to transplant failure. We have
chosen this therapy with two immunosuppressive medications
based upon the biology of the BK virus. This virus hijacks the
cellular machinery to reproduce itself, and in passing activates
inflammation and scarring. Our therapy will interrupt this process,
and result in less scarring and will maintain renal transplant
function.
Department
Program
Randomized Controlled Trials
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
178728
Name
Tibbles Lee Anne
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Randomized Controlled Trials - B (RFB)
Projecttitle
The BK: KIDNI Trial (BK: Kinase Inhibition to Decrease Nephropathy Intervention Trial)
Programtype2
Randomized Controlled Trials
Orgnameinp2
University of Calgary
Cihramount2
$3,319,686
Cihrequipment2
$0
Programname2
Randomized Controlled Trials
Keyworddelim
Bk Virus; Chronic Allograft Nephropathy; Inflammation And Fibrosis; Randomized Controlled Clinical Trial; Sirolimus And Leflunomide; Transplant Failure
Abstract
This is a randomized controlled trial to determine whether specific
therapy aimed at reducing viral damage to the transplant kidney
will have a better outcome than standard therapy, which currently
consists of reducing immunosuppression. Infection with the BK
virus in kidney transplants can lead to transplant failure. We have
chosen this therapy with two immunosuppressive medications
based upon the biology of the BK virus. This virus hijacks the
cellular machinery to reproduce itself, and in passing activates
inflammation and scarring. Our therapy will interrupt this process,
and result in less scarring and will maintain renal transplant
function.
Competitiondate
200902
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Tibbles, Lee Anne; Hemmelgarn, Brenda R; Manns, Braden J
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $3,319,686~ $0~
